Alkermes Engages at Goldman Sachs Global Healthcare Event
Alkermes Engages at Goldman Sachs Global Healthcare Event
Alkermes plc, known for its commitment to neuroscience, is set to participate in the prestigious Goldman Sachs 46th Annual Global Healthcare Conference. This significant event will take place on a Monday with the exact time to be determined later.
Invitation to the Event
The management team at Alkermes will take part in an engaging fireside chat presentation. This is a fantastic platform for them to discuss recent advancements and future directions in their innovative pipeline.
Live Streaming and Accessibility
Individuals interested in tuning into the event can access the live webcast via the Investors tab on Alkermes’ official website. Furthermore, the recording of this insightful session will be available for a period of 14 days, making it convenient for stakeholders and the public alike.
About Alkermes plc
Alkermes plc is a dynamic global biopharmaceutical company dedicated to pioneering novel medicines primarily in the field of neuroscience. The company boasts an impressive portfolio of proprietary products aimed at treating challenging conditions such as alcohol and opioid dependence, schizophrenia, and bipolar I disorder.
Innovative Drug Development
As part of their focused effort to address neurological disorders, Alkermes is also investing in clinical and preclinical research. Their innovative pipeline includes potential treatments for narcolepsy and idiopathic hypersomnia, showcasing their commitment to patient-focused solutions.
Global Presence and Operations
Headquartered in Ireland, Alkermes extends its influence globally with a corporate office and research and development center located in Massachusetts, along with a state-of-the-art manufacturing facility in Ohio. This robust operational structure allows the company to efficiently advance its research initiatives and product offerings.
Company Contact Information
For inquiries related to investors or media, the primary contact at Alkermes is Jamie Constantine, who oversees Investor Relations. Jamie can be reached at +1 781 873 2402 for any detailed questions or further discussions about Alkermes’ strategy and portfolio.
Frequently Asked Questions
What is the Goldman Sachs Global Healthcare Conference?
This event is an annual gathering of healthcare industry leaders, where companies present insights into their operations and advancements.
Who is Alkermes plc?
Alkermes plc is a biopharmaceutical company focused on developing innovative therapies for neurological and mental health conditions.
How can I access the conference presentation?
The presentation can be accessed live through the Investors tab on Alkermes' official website and will be available for 14 days post-event.
What products does Alkermes offer?
Alkermes offers several proprietary products for treating alcohol dependence, opioid dependence, and other mental health disorders.
Who should I contact for more information about Alkermes?
You can reach out to Jamie Constantine, the head of Investor Relations, at +1 781 873 2402.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
